Posts Tagged ‘common cold’
Nasodine Patent Allowed in Canada
Highlights Firebrick Pharma Limited (ASX:FRE) is pleased to announce that its core patent covering Nasodine® Nasal Spray as a treatment and preventative for the common cold has now been allowed in Canada. Once this proceeds to grant, it will bring the number of countries where this patent has been granted to 28, now covering North…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine® Nasal Spray has closed for recruitment.
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week.
Firebrick pursues development of Nasodine for use in children
Firebrick Pharma is pleased to announce that the Paediatric Investigation Plan (PIP) for Nasodine Nasal Spray has been filed with the European Medicines Agency (EMA) Paediatric Committee (PDCO), in preparation for filing for marketing approval of Nasodine in Europe later this year. A Paediatric Investigation Plan or ‘PIP’ is a development plan aimed at ensuring…
Firebrick’s international trial gets radio spotlight
Executive Chairman Peter Molloy speaks with 3BA Radio about Firebrick’s international trial targeting the common cold.
Nasodine composition patent accepted in Australia
Firebrick Pharma Limited is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray has been accepted in Australia.
Update on Nasodine Phase 3 trial
Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…
Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
Firebrick Pharma’s Dr Peter Molloy and Dr Chris Rock from CMAX Clinical Research discuss with Channel 7 the start of our Phase 3 common cold trial for Nasodine® Nasal Spray. Adelaide is the first location for the trial, with sites in Victoria and South Africa to follow. If you live in South Australia or Victoria,…